Insider Selling: Insmed (NASDAQ:INSM) CFO Sells 1,447 Shares of Stock

08 Jan 2026, 19:21 by Renee Jackson · The Cerbat Gem

Insmed, Inc. (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 1,447 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $174.17, for a total transaction of $252,023.99. Following the transaction, the chief financial officer directly owned 80,506 shares of the company’s stock, valued at $14,021,730.02. This represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Sara Bonstein also recently made the following trade(s):

On Wednesday, January 7th, Sara Bonstein sold 1,678 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $293,767.46.
On Tuesday, January 6th, Sara Bonstein sold 1,517 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total transaction of $262,941.61.

Insmed Stock Performance

Shares of Insmed stock traded down $5.73 during trading on Thursday, hitting $170.27. 2,588,589 shares of the company’s stock were exchanged, compared to its average volume of 2,142,398. The stock has a market capitalization of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08. The business has a 50-day simple moving average of $190.79 and a 200-day simple moving average of $151.24. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63.

Insmed (NASDAQ:INSM – Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The business had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. Insmed’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.27) earnings per share. On average, research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently added to or reduced their stakes in INSM. CIBC Private Wealth Group LLC increased its holdings in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares in the last quarter. ORG Partners LLC lifted its holdings in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares in the last quarter. Hilltop National Bank acquired a new stake in shares of Insmed in the second quarter valued at about $28,000. Stone House Investment Management LLC purchased a new stake in shares of Insmed during the third quarter worth about $29,000. Finally, SBI Securities Co. Ltd. raised its position in shares of Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares during the last quarter.

Key Insmed News

Here are the key news stories impacting Insmed this week:

Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

Wall Street Analysts Forecast Growth

INSM has been the subject of a number of analyst reports. Bank of America boosted their price target on Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a report on Monday, October 27th. Royal Bank Of Canada cut their target price on shares of Insmed from $215.00 to $195.00 and set an “outperform” rating for the company in a report on Thursday, December 18th. Truist Financial started coverage on shares of Insmed in a report on Friday, December 19th. They set a “buy” rating and a $202.00 price target on the stock. Cantor Fitzgerald raised their price target on shares of Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Finally, Wedbush set a $203.00 price objective on shares of Insmed in a report on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $205.64.

Get Our Latest Research Report on INSM

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.